BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Sold by Schroder Investment Management Group

Schroder Investment Management Group cut its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 94.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 218,964 shares of the biotechnology company’s stock after selling 3,860,485 shares during the quarter. Schroder Investment Management Group owned about 0.11% of BioMarin Pharmaceutical worth $14,393,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of BMRN. FMR LLC boosted its holdings in BioMarin Pharmaceutical by 21.7% during the third quarter. FMR LLC now owns 206,538 shares of the biotechnology company’s stock worth $14,518,000 after buying an additional 36,877 shares in the last quarter. Quantbot Technologies LP acquired a new stake in shares of BioMarin Pharmaceutical during the 3rd quarter valued at $171,000. Glenmede Trust Co. NA bought a new stake in shares of BioMarin Pharmaceutical during the 3rd quarter worth $254,000. Captrust Financial Advisors grew its holdings in shares of BioMarin Pharmaceutical by 34.1% in the 3rd quarter. Captrust Financial Advisors now owns 10,900 shares of the biotechnology company’s stock worth $766,000 after acquiring an additional 2,770 shares during the last quarter. Finally, Paloma Partners Management Co acquired a new stake in shares of BioMarin Pharmaceutical during the third quarter worth $239,000. 98.71% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CAO Erin Burkhart sold 1,295 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $71.52, for a total value of $92,618.40. Following the transaction, the chief accounting officer now owns 16,955 shares of the company’s stock, valued at $1,212,621.60. This trade represents a 7.10 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 1.85% of the company’s stock.

BioMarin Pharmaceutical Stock Down 1.2 %

BioMarin Pharmaceutical stock opened at $67.48 on Friday. The company has a market capitalization of $12.87 billion, a P/E ratio of 30.67, a P/E/G ratio of 0.61 and a beta of 0.30. BioMarin Pharmaceutical Inc. has a 1-year low of $60.63 and a 1-year high of $94.85. The firm’s fifty day simple moving average is $67.98 and its 200-day simple moving average is $67.31. The company has a current ratio of 5.33, a quick ratio of 2.62 and a debt-to-equity ratio of 0.11.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings results on Wednesday, February 19th. The biotechnology company reported $0.72 earnings per share for the quarter, topping analysts’ consensus estimates of $0.54 by $0.18. The company had revenue of $747.31 million during the quarter, compared to analysts’ expectations of $711.05 million. BioMarin Pharmaceutical had a return on equity of 9.91% and a net margin of 14.96%. Sell-side analysts forecast that BioMarin Pharmaceutical Inc. will post 3.15 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on BMRN shares. Scotiabank increased their price target on BioMarin Pharmaceutical from $78.00 to $80.00 and gave the company a “sector perform” rating in a research report on Thursday, February 20th. Bank of America lifted their target price on shares of BioMarin Pharmaceutical from $99.00 to $103.00 and gave the stock a “buy” rating in a research report on Thursday, February 20th. UBS Group upped their price target on shares of BioMarin Pharmaceutical from $109.00 to $113.00 and gave the company a “buy” rating in a research report on Thursday, February 20th. Citigroup lifted their price objective on shares of BioMarin Pharmaceutical from $81.00 to $82.00 and gave the stock a “neutral” rating in a research report on Thursday, February 20th. Finally, Royal Bank of Canada restated a “sector perform” rating and issued a $70.00 target price on shares of BioMarin Pharmaceutical in a report on Thursday, February 20th. Seven analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $94.00.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.